Approval sought for trials of new treatment at HCG Hospital – The New Indian Express

Express News Service

BENGALURU:   HCG Hospital plans to propose to the government two new clinical trials related to treatment methods for Covid-19 patients. One of these is called Mesenchymal cell study for patients with Acute Respiratory Distress Syndrome (ARDS) where Mesenchymal stem cells from the bone marrow are given to the patient.

The other is developing a non-invasive test called neutralising antibody assay which will help find out at what concentration of antibodies present in the donor’s plasma does the coronavirus get killed. Dr U S Vishal Rao, head and neck surgical oncologist and robotic surgeon, who is also the member of the Covid consultative group in Karnataka, said, “Mesenchymal cell study is meant for patients with ARDS, are critically ill, on ventilator and can’t breathe.

Mesenchymal stem cells from the bone marrow will be infused in the patient’s body through injection over a period of a few hours.” These cells are being taken as they have anti-inflammatory properties.

They reduce the cytokine storm and reduce inflammation in the lungs. The aim here is to prevent death. The team at the hospital is waiting for inspection and approval from the Drugs Controller General of India (DCGI). The neutralising antibody assay test will also require DCGI approval as well as approval from the Indian Council of Medical Research (ICMR). If the antibodies in the plasma of the Covid-recovered donor are low, it will not work on the corona positive patient.

This test helps determine the number